Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MESO-CAR T Cells for Relapsed/Refractory Ovarian Cancer
NCT03799913Phase 1Unknown
- Sponsor
- Zhejiang University
- Start
- Apr 2019
- Primary completion
- Oct 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-mesothelin CAR vector-transduced autologous T lymphocytes in ovarian cancer, sponsored by Zhejiang University. Primary endpoint: Occurrence of study related adverse effects at 1 year. Status: unknown.
02
Drugs
anti-mesothelin CAR vector-transduced autologous T lymphocytes
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03799913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03799913.